A phase I study investigation of metabolism, and disposition of [
Adenocarcinoma of Lung
/ drug therapy
Administration, Oral
Antineoplastic Agents
/ administration & dosage
Colorectal Neoplasms
/ drug therapy
Drug Monitoring
/ methods
Humans
Indoles
/ administration & dosage
Kidney Neoplasms
/ drug therapy
Liver
/ metabolism
Male
Metabolic Clearance Rate
Metabolic Detoxication, Phase I
Middle Aged
Neoplasm Staging
Protein-Tyrosine Kinases
/ antagonists & inhibitors
Quinolines
/ administration & dosage
Radiopharmaceuticals
/ administration & dosage
Sarcoma
/ drug therapy
Tissue Distribution
Treatment Outcome
Anlotinib hydrochloride
Metabolism
Pharmacokinetics
Phase I study
Journal
Cancer chemotherapy and pharmacology
ISSN: 1432-0843
Titre abrégé: Cancer Chemother Pharmacol
Pays: Germany
ID NLM: 7806519
Informations de publication
Date de publication:
05 2020
05 2020
Historique:
received:
02
08
2019
accepted:
19
03
2020
pubmed:
9
4
2020
medline:
18
11
2020
entrez:
9
4
2020
Statut:
ppublish
Résumé
Anlotinib is a novel oral multi-targeted receptor tyrosine kinase inhibitor, which selectively inhibits VEGFR2/3, FGFR1-4, PDGFR α/β, c-kit, and Ret. It shows antitumor effect in patients with advanced refractory solid tumors. The detailed absorption, metabolism, and excretion pathways of anlotinib have not yet been fully investigated. Six male patients were enrolled and divided into two groups. Group A (containing two patients) received 14.15 mg/80 µCi/subject [ In plasma, the average time to peak concentration (T Anlotinib had a good pharmacokinetic profile with rapid absorption, long half-life, and extensive hepatic metabolism. The adverse events and efficacy were as expected.
Identifiants
pubmed: 32266457
doi: 10.1007/s00280-020-04062-8
pii: 10.1007/s00280-020-04062-8
pmc: PMC7188728
doi:
Substances chimiques
Antineoplastic Agents
0
Indoles
0
Quinolines
0
Radiopharmaceuticals
0
anlotinib
0
Protein-Tyrosine Kinases
EC 2.7.10.1
Types de publication
Clinical Trial, Phase I
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
907-915Références
Int J Gynecol Cancer. 2018 Jan;28(1):152-160
pubmed: 28953502
Bioorg Med Chem Lett. 2016 Jan 15;26(2):534-539
pubmed: 26639762
J Hematol Oncol. 2018 Sep 19;11(1):120
pubmed: 30231931
Gene. 2018 May 15;654:77-86
pubmed: 29454091
Lung Cancer. 2018 Aug;122:32-37
pubmed: 30032842
Biomed Res Int. 2017;2017:3619723
pubmed: 29441353
J Chromatogr B Analyt Technol Biomed Life Sci. 2016 Oct 15;1033-1034:390-398
pubmed: 27639128
Br J Cancer. 2019 Mar;120(5):512-521
pubmed: 30765873
J Hematol Oncol. 2016 Oct 4;9(1):105
pubmed: 27716285
Zhongguo Fei Ai Za Zhi. 2018 May 20;21(5):428-430
pubmed: 29764596
Acta Pharmacol Sin. 2018 Jun;39(6):1048-1063
pubmed: 29620050
J Exp Clin Cancer Res. 2019 Jan 28;38(1):41
pubmed: 30691487
Onco Targets Ther. 2018 Dec 18;12:57-61
pubmed: 30588030
Drugs. 2018 Jul;78(10):1057-1062
pubmed: 29943374
Int J Cancer. 2019 Aug 15;145(4):979-993
pubmed: 30719715